Axsome Therapeutics今天将在纳斯达克股票市场敲响开盘钟-动脉网

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Axsome Therapeutics 等信源发布 2025-07-21 19:26



可切换为仅中文







Download PDF

下载PDF

NEW YORK

纽约

，

July 21, 2025

2025年7月21日

(GLOBE NEWSWIRE) --

（环球新闻网）——

Axsome Therapeutics, Inc.

(NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that

（纳斯达克股票代码：AXSM），一家引领中枢神经系统（CNS）疾病治疗新时代的生物制药公司，今天宣布

Herriot Tabuteau

埃里奥特·塔布托

, MD, Axsome’s Chief Executive Officer, along with the rest of the management team, and other Axsome team members, will ring the opening bell of the

，医学博士，Axsome首席执行官，与管理团队其他成员及其他Axsome团队成员一起，将敲响开盘铃。

NASDAQ Stock Market

纳斯达克股票市场

today,

今天，

Monday, July 21, 2025

2025年7月21日，星期一

, in connection with its Frontiers in Brain Health R&D Day event being held today.

，与其今天举行的脑健康研发前沿日活动相关。

Herriot Tabuteau

埃里奥·塔布特

, MD, Chief Executive Officer of Axsome said, “We are thrilled to ring NASDAQ’s opening bell in connection with our Frontiers in Brain Health R&D Day today, showcasing our pioneering work across our pipeline of innovative, late-stage CNS product candidates, and commemorating the recent availability of SYMBRAVO.

医学博士、Axsome首席执行官表示：“我们非常高兴在今天与我们举办的‘大脑健康前沿研发日’活动相关联之际敲响纳斯达克开盘钟，展示我们在创新的晚期中枢神经系统产品管线中的开创性工作，并纪念SYMBRAVO近期的上市。”

by prescription in the

通过处方在

U.S.

美国

With our growing portfolio of differentiated on-market medicines, and our pipeline of potentially transformative investigational medicines, Axsome is defining the future of clinical practice in brain health to improve the lives of the millions of patients living with serious and difficult-to-treat CNS conditions.”.

“随着我们在市场上不断扩大的差异化药物组合，以及我们潜在具有变革性的研究药物管线，Axsome 正在定义脑健康临床实践的未来，以改善数百万患有严重且难以治疗的中枢神经系统疾病患者的生活。”

The opening bell ceremony will take place at the Nasdaq MarketSite located in

开盘铃声仪式将在位于纳斯达克市场内的纳斯达克市场站点举行，

Times Square

时代广场

，

New York, NY

纽约，纽约州

. The live ceremonies will begin at

现场仪式将于

9:20 a.m. Eastern Time

东部时间上午9点20分

and can be viewed at

并且可以查看

https://www.nasdaq.com/marketsite/bell-ringing-ceremony

。

About

关于

Axsome Therapeutics

is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes.

是一家引领中枢神经系统（CNS）疾病治疗新时代的生物制药公司。我们通过识别护理中的关键差距来实现科学突破，并专注于新型作用机制开发差异化产品，从而推动患者治疗结果的显著进步。

Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in .

我们行业领先的神经科学产品组合包括FDA批准的用于治疗重度抑郁症、与嗜睡症和阻塞性睡眠呼吸暂停相关的白天过度嗜睡以及偏头痛的药物，还包含多个针对广泛严重神经和精神疾病的晚期开发项目，这些疾病影响着超过1.5亿人。

the United States

美国

. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at

。我们一起致力于解决大脑的一些最大问题，以便患者及其亲人能够茁壮成长。欲了解更多信息，请访问我们的网站

www.axsome.com

and follow us on

关注我们

领英

and

和

。

Forward Looking Statements

前瞻性声明

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

本新闻稿中讨论的某些事项属于“前瞻性陈述”。公司在某些情况下可能会使用“预测”、“相信”、“潜在”、“继续”、“估计”、“预期”、“计划”、“意图”、“可能”、“能够”、“也许”、“将”、“应该”等词语来表达未来事件或结果的不确定性，以此识别这些前瞻性陈述。

In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI.

特别是，公司关于趋势和潜在未来结果的声明是此类前瞻性陈述的例子。前瞻性陈述包含风险和不确定性，包括但不限于公司SUNOSI的商业成功。

, AUVELITY

，AUVELITY

, and SYMBRAVO

，以及SYMBRAVO

products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain .

产品以及公司为solriamfetol和/或AXS-05获得任何额外适应症的努力的成功；公司维持和扩大支付方覆盖的能力；公司正在进行的临床试验及预计进行的临床试验的成功、时间安排和成本，包括关于试验启动时间、入组速度和完成情况的声明（包括公司完全资助其已披露临床试验的能力，这假设公司目前预计的收入或支出没有重大变化）、无效性分析及中期结果的接收，这些结果不一定代表公司正在进行的临床试验的最终结果，和/或数据读出，以及支持公司当前任何产品候选者提交新药申请（“NDA”）所需的研究所数量或类型或结果性质；公司为继续推进其产品候选者而资助额外临床试验的能力；以及公司获取和维持的时间和能力。

U.S. Food and Drug Administration

美国食品药品监督管理局

(“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control.

（“FDA”）或其他监管机构对公司产品候选物的批准或其他行动，包括任何NDA提交的时间安排；公司成功捍卫其知识产权或以公司可接受的成本获得必要许可的能力（如果可能的话）；公司成功解决任何知识产权诉讼的能力，即使这些争议得以解决，相关联邦机构是否会批准此类和解；公司研发项目及合作的成功实施；公司许可协议的成功执行；市场对公司产品及其候选产品的接受程度（如获批准）；公司预期的资本需求，包括用于SUNOSI、AUVELITY和SYMBRAVO商业化的资本以及公司其他候选产品（如获批准）商业化发布的资金需求，并对公司的预期现金跑道产生的潜在影响；公司将销售额转化为确认收入并保持有利的毛利与净销售额的能力；由于国内政治气候、地缘政治冲突或全球性疫情及其他因素导致的业务运营意外情况或其他中断，包括一般经济状况和不受公司控制的监管发展。

The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking sta.

本文讨论的因素可能导致实际结果和发展与这些陈述所表达或暗示的存在重大差异。前瞻性声明仅在本新闻稿发布之日作出，公司不承担公开更新此类前瞻性声明的义务。

Investors:

投资者：

Mark Jacobson

马克·雅各布森

Chief Operating Officer

首席运营官

(212) 332-3243

mjacobson@axsome.com

Media:

媒体：

Darren Opland